FDA Change Impact Assessment for Medical Devices

Section 513(g) of the FD&C Act allows a manufacturer to request FDA's views on the classification and regulatory requirements that may apply to a medical device. It is commonly used when a company needs clarity on device classification, applicable regulations, or the likely premarket pathway. A 513(g) response is informative, but it is not a clearance or approval.

FDA's target timeline for responding to a 513(g) request is generally 60 days after receipt, although actual timing can vary depending on agency workload and the completeness of the submission. A well-prepared request with a clear device description, intended use, and supporting rationale helps reduce avoidable delays and improves the usefulness of the response.

An FDA change impact assessment is a structured review of a modification to an already cleared or approved device to determine whether the change affects safety, effectiveness, intended use, or regulatory status. It evaluates design, software, labeling, materials, manufacturing, and process changes against FDA guidance and documents whether a new submission, supplement, or internal justification is appropriate.

A new 510(k) may be required when a change could significantly affect the device's safety or effectiveness, or when there is a major change in intended use. Common triggers include significant software modifications, design changes affecting performance, new materials, revised sterilization methods, or labeling changes that alter indications or claims. A documented assessment is essential before implementation.

Yes. Labeling and IFU changes can trigger FDA action if they alter intended use, indications, contraindications, warnings, operating parameters, or performance claims. Even when no new submission is required, the rationale should still be documented within change control records. Careful review helps prevent introducing claims or instructions that exceed the scope of the existing clearance or approval.

Typical inputs include the current clearance or approval, device description, intended use statements, risk management files, verification and validation data, software documentation, labeling, design history records, complaint or PMS data, and change control records. Reviewing these materials together helps establish whether the modification remains within the existing regulatory basis or requires additional FDA engagement.

The timeline depends on the complexity of the device, the number of affected markets, and the quality of the existing documentation. Straightforward labeling or administrative changes may be assessed quickly, while software, design, or manufacturing changes often require deeper review of testing, risk, and traceability records. A structured assessment upfront usually saves far more time than correcting a weak decision later.

Documenting the rationale is critical because FDA inspectors and auditors expect to see evidence that changes were evaluated systematically before implementation. A complete record shows what changed, what guidance was applied, what evidence was reviewed, and why the company concluded that no new submission was required. That documentation protects the business during inspections, audits, and future submissions.